Junaid Mian, RPh

Coming from a space perspective enables EarthLighters to apply both the micro and macro lessons the opening of this new domain offers us. At the macro level, space provides the ability to study, understand, and act on challenges the human economy is causing to the planet as a whole. At a more micro and personal level, EarthLighters are called to be their “higher selves.” Be it the spiritual transformation known as the Overview Effect – felt by those who bathe in EarthLight and look back on Gia from space – or feel the wonder and power of the gift of life. The MotherWorld gives us or an understanding of our absolute union with and responsibility to one another; our goals are to expand the domain of life and our own lives. EarthLight is about all of us and all about you. It is time to rise above what you have been and embrace what you can become. Join us: https://earthlightfoundation.org/join-e-l-f/

Orbit Fab envisions a thriving in-space market for products and services that support both existing space businesses (communications and Earth observation) and new industries like space tourism, manufacturing, and mining. The first step is achieving ubiquitous availability of satellite propellant in Earth orbit, expanding the operational potential of new and existing space assets and providing unprecedented business model flexibility for satellite owners. The future for satellites is no longer restricted to the fuel they are launched with. It is about getting the fuel and other materials they need, where and when they need it, to accomplish things never before thought possible.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com.

Solstar Space is the leading commercial space-based connectivity company pioneering the use of persistent communications services for all types of on-orbit assets including satellites, space stations, launch vehicles, and more. We provide an internet connection between spacecraft and payload managers, satellite operators, and enable orbital and suborbital communications for crewed missions. Our fast, reliable services, space-tested routers, Wi-Fi access points, and hotspots, and satellite space communicators and data relays are being developed to deliver on-orbit persistent connectivity and are supported by 24/7 customer care. These assets are installed on satellites and spacecraft prior to launch to keep crew, spacecraft, and Earth-based satellite operations teams connected. Solstar is a mobile satellite services (MSS) company founded to provide commercial Internet Protocol (IP) data, local Wi-Fi, and voice communications services for astronauts and things in space. Solstar’s modern space-to-ground communications services use existing and emerging commercial satellite constellation networks. Meaning, Solstar does not need to launch its own satellite constellation and we leverage $billions of satellite networks paid for by others. This makes sense since Solstar and its heritage companies have established suppliers and professionals built over the past 22 years. Solstar was formed specifically to provide commercial satellite communications services for space-to-space and space-to-ground applications. Solstar’s founders have owned and operated three MSS companies since 1999. Solstar’s business is the result of 12 years of internal research and development (IR&D) investment to develop space communications technologies. We also leverage our unfunded Space Act Agreement (SAA) with NASA’s Flight Opportunities Program (FOP) awarded to Solstar in 2013, to mature our space communications technology.

Axiom Space is a human space exploration company, building era-defining space infrastructure and delivering technology-driven solutions that will empower civilization to transcend Earth. Beginning with Axiom Station, successor to the International Space Station, the company is pioneering a next-generation orbital settlement that will foster groundbreaking innovation and research in microgravity and drive the global space economy of tomorrow. Today, guided by the vision of leading humanitys expansion off planet, Axiom Space is the principal provider of commercial human spaceflight services and developer of advanced spacesuits for the Moon and beyond. Connect with us: instagram.com/axiom.space/ twitter.com/axiom_space facebook.com/axiomspace/ youtube.com/axiomspace

We are scientists, medical practitioners, biohackers, and health conscious creators sharing our knowledge and techniques to help optimize the quality of your life—beginning with your mind. Creators of the Qualia supplement line.

1435 Capital Management is an industry agnostic venture capital firm focused on investing in Seed through Series B companies.

Coming from a space perspective enables EarthLighters to apply both the micro and macro lessons the opening of this new domain offers us. At the macro level, space provides the ability to study, understand, and act on challenges the human economy is causing to the planet as a whole. At a more micro and personal level, EarthLighters are called to be their “higher selves.” Be it the spiritual transformation known as the Overview Effect – felt by those who bathe in EarthLight and look back on Gia from space – or feel the wonder and power of the gift of life. The MotherWorld gives us or an understanding of our absolute union with and responsibility to one another; our goals are to expand the domain of life and our own lives. EarthLight is about all of us and all about you. It is time to rise above what you have been and embrace what you can become. Join us: https://earthlightfoundation.org/join-e-l-f/

SpaceFund is a Venture Capital firm focused on supporting and investing in the growth of the space economy. Our team has the extensive industry experience and a strategic investment approach. By backing innovative ventures and leveraging our portfolio, we aim to drive the development of the space industry and generate solid returns for our investors. Our focus is on building a sustainable future for space exploration and improving peoples lives on Earth and beyond. If you are interested in supporting the space industrys growth and exploring potential investment opportunities, we welcome the opportunity to speak with you.

Orbit Fab envisions a thriving in-space market for products and services that support both existing space businesses (communications and Earth observation) and new industries like space tourism, manufacturing, and mining. The first step is achieving ubiquitous availability of satellite propellant in Earth orbit, expanding the operational potential of new and existing space assets and providing unprecedented business model flexibility for satellite owners. The future for satellites is no longer restricted to the fuel they are launched with. It is about getting the fuel and other materials they need, where and when they need it, to accomplish things never before thought possible.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com.